A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses - An imaging-based study with controls

Anup Mathew Joseph, Ganesan Venkatasubramanian, Podila Satya Venkata Narasimha Sharma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: To measure the changes in subcutaneous and intra-abdominal fat and other metabolic parameters in patients with psychotic disorders, who were newly started on olanzapine treatment and in drug-free controls. The correlation between changes in visceral fat and other metabolic parameters were also studied. Methods: Using a longitudinal open-label design, the 2 studied groups included patients with psychoses (n = 23) [diagnosed as per the 10th edition of the International Classification of Diseases criteria] and drug-free controls (n = 11). Fasting sugar, lipid profile and glycosylated haemoglobin levels were collected at baseline and follow-up. Computed tomographic scans were used to determine changes in the various abdominal fat parameters. Results: The patients were significantly younger than the controls, and the former had higher mean subcutaneous fat at baseline. There were statistically significant increases in the subcutaneous fat, intra-abdominal fat, weight, waist circumference, hip circumference and body mass index in patients but not in controls. The mean dose of olanzapine (mg / day) correlated significantly with change of intra-abdominal fat at follow-up. The change in intra-abdominal fat did not correlate significantly with any of the metabolic parameters studied. Conclusions: Olanzapine produced significant increase in weight and fat parameters. This increase correlated with the dose of olanzapine.

Original languageEnglish
Pages (from-to)10-16
Number of pages7
JournalEast Asian Archives of Psychiatry
Volume21
Issue number1
Publication statusPublished - 01-03-2011

Fingerprint

olanzapine
Abdominal Fat
Intra-Abdominal Fat
Psychotic Disorders
Drug and Narcotic Control
Subcutaneous Fat
Weights and Measures
Glycosylated Hemoglobin A
Waist Circumference
International Classification of Diseases
Hip
Fasting
Body Mass Index
Fats
Lipids

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

@article{708d99f0b30c4850b4578ad33ed0b00f,
title = "A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses - An imaging-based study with controls",
abstract = "Objectives: To measure the changes in subcutaneous and intra-abdominal fat and other metabolic parameters in patients with psychotic disorders, who were newly started on olanzapine treatment and in drug-free controls. The correlation between changes in visceral fat and other metabolic parameters were also studied. Methods: Using a longitudinal open-label design, the 2 studied groups included patients with psychoses (n = 23) [diagnosed as per the 10th edition of the International Classification of Diseases criteria] and drug-free controls (n = 11). Fasting sugar, lipid profile and glycosylated haemoglobin levels were collected at baseline and follow-up. Computed tomographic scans were used to determine changes in the various abdominal fat parameters. Results: The patients were significantly younger than the controls, and the former had higher mean subcutaneous fat at baseline. There were statistically significant increases in the subcutaneous fat, intra-abdominal fat, weight, waist circumference, hip circumference and body mass index in patients but not in controls. The mean dose of olanzapine (mg / day) correlated significantly with change of intra-abdominal fat at follow-up. The change in intra-abdominal fat did not correlate significantly with any of the metabolic parameters studied. Conclusions: Olanzapine produced significant increase in weight and fat parameters. This increase correlated with the dose of olanzapine.",
author = "Joseph, {Anup Mathew} and Ganesan Venkatasubramanian and Sharma, {Podila Satya Venkata Narasimha}",
year = "2011",
month = "3",
day = "1",
language = "English",
volume = "21",
pages = "10--16",
journal = "East Asian Archives of Psychiatry",
issn = "2078-9947",
publisher = "Hong Kong Academy of Medicine Press",
number = "1",

}

TY - JOUR

T1 - A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses - An imaging-based study with controls

AU - Joseph, Anup Mathew

AU - Venkatasubramanian, Ganesan

AU - Sharma, Podila Satya Venkata Narasimha

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Objectives: To measure the changes in subcutaneous and intra-abdominal fat and other metabolic parameters in patients with psychotic disorders, who were newly started on olanzapine treatment and in drug-free controls. The correlation between changes in visceral fat and other metabolic parameters were also studied. Methods: Using a longitudinal open-label design, the 2 studied groups included patients with psychoses (n = 23) [diagnosed as per the 10th edition of the International Classification of Diseases criteria] and drug-free controls (n = 11). Fasting sugar, lipid profile and glycosylated haemoglobin levels were collected at baseline and follow-up. Computed tomographic scans were used to determine changes in the various abdominal fat parameters. Results: The patients were significantly younger than the controls, and the former had higher mean subcutaneous fat at baseline. There were statistically significant increases in the subcutaneous fat, intra-abdominal fat, weight, waist circumference, hip circumference and body mass index in patients but not in controls. The mean dose of olanzapine (mg / day) correlated significantly with change of intra-abdominal fat at follow-up. The change in intra-abdominal fat did not correlate significantly with any of the metabolic parameters studied. Conclusions: Olanzapine produced significant increase in weight and fat parameters. This increase correlated with the dose of olanzapine.

AB - Objectives: To measure the changes in subcutaneous and intra-abdominal fat and other metabolic parameters in patients with psychotic disorders, who were newly started on olanzapine treatment and in drug-free controls. The correlation between changes in visceral fat and other metabolic parameters were also studied. Methods: Using a longitudinal open-label design, the 2 studied groups included patients with psychoses (n = 23) [diagnosed as per the 10th edition of the International Classification of Diseases criteria] and drug-free controls (n = 11). Fasting sugar, lipid profile and glycosylated haemoglobin levels were collected at baseline and follow-up. Computed tomographic scans were used to determine changes in the various abdominal fat parameters. Results: The patients were significantly younger than the controls, and the former had higher mean subcutaneous fat at baseline. There were statistically significant increases in the subcutaneous fat, intra-abdominal fat, weight, waist circumference, hip circumference and body mass index in patients but not in controls. The mean dose of olanzapine (mg / day) correlated significantly with change of intra-abdominal fat at follow-up. The change in intra-abdominal fat did not correlate significantly with any of the metabolic parameters studied. Conclusions: Olanzapine produced significant increase in weight and fat parameters. This increase correlated with the dose of olanzapine.

UR - http://www.scopus.com/inward/record.url?scp=79953826716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953826716&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 10

EP - 16

JO - East Asian Archives of Psychiatry

JF - East Asian Archives of Psychiatry

SN - 2078-9947

IS - 1

ER -